This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F01.0 | Special Copayment Reduction: V810 (severe intractable disease, 5 years) |
| B. Synonyms | No separate synonyms; post-stroke dementia (acute cases) |
| C. Adult onset | Yes — acute onset after stroke; occurs in adults in middle age and later. |
| 1. History | History of vascular dementia; Binswanger (1894) and Marie (1901) described vascular brain lesions; research on the dementia-stroke association; 1993 NINDS-AIREN diagnostic criteria. |
| 2. Causes | Large-vessel cerebral infarction (cardiogenic embolism, atherosclerosis); intracerebral hemorrhage; strategic-location stroke (thalamus, internal capsule, angular gyrus, etc.). |
| 3. Genetics | CADASIL (NOTCH3); MTHFR polymorphism; hypertension- and atherosclerosis-related genes; APOE ε4. |
| 4. General epidemiology | Incidence of post-stroke dementia: about 10% within 1 year after stroke; a portion of all vascular dementia; about 15-20% of dementia in the elderly. |
| 5. Pathophysiology | Ischemia in the cerebral cortex or strategic subcortical regions → neuronal death → network disconnection → abrupt decline in cognitive function. |
| 6. Symptoms | Cognitive decline within a short time (hours to weeks) after stroke onset; focal symptoms by site; stepwise progression. |
| 7. Signs | Focal neurological deficits; infarct and hemorrhagic lesions on brain MRI; Hachinski Ischemic Score. |
| 8. Screening | Post-stroke cognitive assessment protocol; standardized tests such as MoCA; cognitive assessment follow-up at 3-6 months. |
| 9. Diagnosis | NINDS-AIREN or VasCog diagnostic criteria; temporal relationship (cognitive decline after stroke); confirmation of MRI lesions. |
| 10. Treatment | Prevention of stroke recurrence (antithrombotics, control of blood pressure, glucose, and lipids); cognitive rehabilitation; cholinesterase inhibitors (limited evidence). |
| 11. Prognosis | Additional cognitive decline on stroke recurrence; prevention of recurrence determines prognosis; stepwise progression compared with Alzheimer disease. |
| 12. Prevention | Control of vascular risk factors; stroke prevention; anticoagulation for atrial fibrillation; smoking cessation and alcohol moderation. |
| 13. References | Dichgans M, Leys D. Circ Res 2017 and 9 other references |
The history of vascular dementia (VaD) began with the development of neuropathology in the late 19th century. In 1894, Otto Binswanger described a case of dementia progressing with ischemic degeneration of the subcortical white matter, which became the prototype of the disease now known as Binswanger disease or subcortical vascular dementia. In 1901, Pierre Marie described the association between small cerebral vessel lesions (lacunar infarcts) and cognitive decline.
Until the mid-20th century, the cause of senile dementia was explained mainly by 'atherosclerotic cerebrovascular disease,' but with the rediscovery of Alzheimer neuropathology in the 1960s-70s, vascular dementia and Alzheimer dementia began to be distinguished as independent diseases. In 1974, Helge Larrieu and colleagues and Rosen and colleagues developed the Hachinski Ischemic Score, presenting a method for clinically differentiating vascular dementia from Alzheimer dementia.
In 1993, Roman and colleagues published the NINDS-AIREN (National Institute of Neurological Disorders and Stroke - Association Internationale pour la Recherche et l'Enseignement en Neurosciences) diagnostic criteria, establishing a standard for clinical research on vascular dementia. These criteria take cerebrovascular disease (imaging evidence), dementia, and the temporal relationship between the two (onset of dementia within 3 months after stroke) as the core elements.
In 2014, the VasCog (Vascular Impairment of Cognition Classification Consensus Study) group proposed new classification criteria dividing vascular cognitive impairment into mild (vascular mild cognitive impairment, VaMCI) and major vascular cognitive impairment (dementia, major VCI). Vascular dementia of acute onset (F01.0) is a form in which cognitive function declines abruptly within hours to weeks after an infarct in a major cerebral vascular territory or an intracerebral hemorrhage, and is classified under a separate code in ICD-10.
Vascular dementia of acute onset results from abrupt cognitive decline after a single or several strategic-location infarcts (strategic infarct) or a large-vessel cerebral infarction.
Extensive ischemic infarcts in the middle, anterior, and posterior cerebral artery territories can cause abrupt cognitive decline together with stroke symptoms. Cardiogenic emboli (atrial fibrillation, endocarditis, mural thrombus after myocardial infarction) and aortic and carotid atherosclerotic emboli are the main causes.
Small infarcts in regions that are key network hubs for cognitive function, such as the hippocampus, thalamus (especially the medial thalamus and the thalamic polar artery territory), basal forebrain, fornix, prefrontal cortex, angular gyrus, and internal capsule, cause disproportionately severe cognitive decline. Unilateral thalamic infarction can cause abrupt decline in memory, concentration, and level of alertness.
Intracerebral hemorrhage in the basal ganglia, thalamus, and white matter can cause abrupt cognitive decline through the hemorrhage site and compression of surrounding brain tissue. Hypertensive intracerebral hemorrhage is the most common, and lobar hemorrhage due to cerebral amyloid angiopathy (CAA) is also an important cause.
Hypertension, diabetes, atrial fibrillation, heart failure, coronary artery disease, smoking, dyslipidemia, obesity, and decreased renal function are the main risk factors. Hypertension is the strongest risk factor for vascular dementia, increasing stroke risk about 3- to 4-fold.
The genetic background of acute-onset vascular dementia is explained mainly by genetic factors related to vascular risk factors and susceptibility to stroke.
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an autosomal dominant disease caused by mutations in the NOTCH3 gene (chromosome 19), in which dementia due to recurrent lacunar infarcts and white matter degeneration begins in middle age (30s-50s). Because cognitive decline occurs together with acute stroke episodes, it may fall under F01.0 and F01.1.
Genes related to hypertension (AGT, ACE, ADD1, etc.), genes related to susceptibility to thrombus formation (Factor V Leiden, MTHFR C677T), genes related to atrial fibrillation, and genes related to atherosclerosis (APOE) contribute to the risk of acute vascular dementia through stroke risk. APOE ε4 is also a risk factor in vascular dementia, but the association is weaker than in Alzheimer disease.
Vascular dementia is the second most common cause of dementia after Alzheimer disease, accounting for about 15-20% of all dementia. However, as recognition that mixed pathology is common has spread, the proportion of pure vascular dementia is being reassessed. The incidence of post-stroke dementia is about 10-20% within the first 3-6 months after stroke, and new-onset dementia after a first stroke in patients with no prior cognitive decline is about 10%.
It is difficult to determine separately the exact frequency of acute-onset (F01.0) vascular dementia. Dementia due to strategic infarcts is estimated to account for about 10-20% of vascular dementia. The incidence of vascular dementia is reported as about 14-35 per 1,000 per year in those aged 65 and older, and is slightly higher in older ages and in men. In Korea, vascular dementia accounts for about 15-20% of dementia, and the high prevalence of hypertension and diabetes contributes to the risk of vascular dementia.
In acute-onset vascular dementia, cognitive decline arises from abrupt damage to key hubs or connecting pathways of brain networks. Brain function depends on large-scale interconnected networks (default mode network, attention network, executive function network, etc.) rather than on individual regions, so even an infarct in a small region can cause widespread cognitive decline if it damages a network hub.
In ischemic cerebral infarction, the central ischemic area (core) undergoes immediate neuronal death, and the surrounding penumbra can recover depending on reperfusion. If reperfusion is achieved by acute-phase stroke treatment (thrombolytics, endovascular treatment), some cognitive function may recover, but infarcted areas without reperfusion remain as permanent neurological damage. Functional reorganization by neuroplasticity occurs after infarction, but the extent of cognitive recovery is determined by the infarct site and the patient's brain reserve.
After cerebral infarction, a neuroinflammatory response is secondarily activated and may further damage surrounding neural tissue, which is one of the mechanisms by which cognitive function continues to decline after the acute phase.
The most prominent features of acute-onset vascular dementia are the temporal relationship with a stroke event and a stepwise or abrupt pattern of onset.
Abrupt cognitive decline appears within hours to weeks (generally 3 months) after stroke. Depending on the site of damage, various cognitive symptoms appear, such as memory impairment, decreased concentration, decreased executive function, language impairment, visuospatial processing abnormalities, and impaired judgment. In thalamic infarction, decreased level of alertness, abulia, and memory impairment are prominent. In angular gyrus infarction, Gerstmann syndrome (agraphia, acalculia, finger agnosia, left-right confusion) may appear. In damage to the frontal cortex or frontal-subcortical connections, decreased executive function, apathy, and impaired judgment appear.
A characteristic feature is that focal neurological deficits accompanying the stroke (hemiplegia, hemianopia, dysarthria, aphasia) appear together with cognitive impairment. Psychiatric symptoms such as depression, anxiety, emotional changes (emotional incontinence), and apathy are also common.
On physical and neurological examination, focal neurological deficits (hemiplegia, contralateral neglect to the language-dominant hemisphere, dysarthria, dysphagia, visual field defects) are observed. Small-step gait, gait apraxia, and parkinsonism-like gait may appear. Because post-stroke cognitive function does not necessarily correspond to the NIHSS (National Institutes of Health Stroke Scale) score, performing cognitive assessment in parallel from the acute phase of stroke is recommended.
Brain MRI (DWI, FLAIR, T2, SWI) shows acute or subacute cerebral infarct lesions (high DWI signal), prior cerebral infarct lesions (high FLAIR signal), white matter degeneration, microbleeds, and intracerebral hemorrhage. Large-vessel atherosclerosis and vascular stenosis are evaluated by carotid and cerebrovascular ultrasound and CT/MR angiography. To exclude cardiogenic embolic causes such as atrial fibrillation, electrocardiography, prolonged ECG monitoring, and echocardiography are performed.
It is important to assess cognitive function in stroke patients using standardized methods. Acute phase (during hospitalization): perform the MoCA (Montreal Cognitive Assessment) or MMSE together with NIHSS neurological function assessment. In stroke patients, the MoCA assesses multiple domains such as executive function, language, and attention and has high sensitivity for cognitive impairment. Subacute phase and follow-up (3-6 months after stroke): perform comprehensive neuropsychological testing in parallel with the neurorehabilitation program and check for the development of dementia.
In patients with cognitive decline who have vascular risk factors (hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking), brain MRI and neuropsychological testing are performed early to differentiate vascular dementia from Alzheimer dementia. Active management of vascular risk factors at the vascular cognitive impairment (VaMCI) stage can prevent progression to dementia.
Diagnosis of acute-onset vascular dementia (F01.0) requires that all three criteria be met: ① dementia criteria met (multidomain cognitive decline confirmed by neuropsychological testing + decline in daily function), ② neuroimaging evidence of cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), and ③ a temporal relationship between dementia and cerebrovascular disease (onset of cognitive decline within 3 months after stroke, or abrupt cognitive decline after stroke).
Diagnostic tools: use the VasCog 2014 criteria or the NINDS-AIREN 1993 criteria. Neuroimaging criteria for vascular dementia: cortical/subcortical cerebral infarcts, extensive white matter hyperintensity (Fazekas grade 2 or higher), strategic-location infarcts. In differentiation from Alzheimer disease, amyloid PET or cerebrospinal fluid biomarkers (A-T-N-) help exclude Alzheimer pathology in vascular dementia.
Treatment of acute-onset vascular dementia consists of ① acute-phase stroke treatment, ② prevention of recurrence, ③ cognitive rehabilitation, and ④ symptomatic treatment.
Acute-phase stroke treatment: In ischemic stroke, neuronal salvage through reperfusion by intravenous t-PA (within 4.5 hours of symptom onset) and mechanical thrombectomy (within 24 hours if indications are met) also has a positive effect on cognitive prognosis. In intracerebral hemorrhage, blood pressure control, reversal of anticoagulants, and surgical hematoma evacuation if needed are performed.
Prevention of recurrence: Oral anticoagulants (NOAC or warfarin) if atrial fibrillation is present, and antiplatelet agents (aspirin, clopidogrel, cilostazol) in noncardiogenic ischemic stroke. Blood pressure control (target SBP <130 mmHg), diabetes control (HbA1c <7.0%), hyperlipidemia treatment (statins), smoking cessation, alcohol moderation.
Cognitive rehabilitation: Targeted cognitive training for the impaired cognitive domains (memory, attention, executive function, language), occupational therapy, and speech therapy contribute to functional recovery.
Symptomatic treatment: The effect of cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine in vascular dementia is supported by weaker evidence than in Alzheimer disease, but benefit has been reported in some clinical trials. Appropriate drug treatment for depression, anxiety, and sleep disorders is needed.
The prognosis of acute-onset vascular dementia varies greatly depending on stroke recurrence, infarct size and location, and the degree of control of accompanying vascular risk factors. Vascular dementia shows higher mortality than Alzheimer disease (within 1-2 years), largely owing to the stroke itself and cardiovascular complications. With active control of vascular risk factors and no stroke recurrence, cognitive function may stabilize or even partially improve.
In dementia due to strategic infarcts, when the infarcted area is limited, some cognitive function may improve over time through functional compensation by other brain regions and neuroplasticity. However, if recurrent strokes occur, additional cognitive decline progresses in a stepwise manner.
Prevention of acute vascular dementia is directly tied to stroke prevention. Primary prevention: hypertension treatment (target blood pressure <130/80 mmHg), diabetes control (HbA1c <7%), hyperlipidemia treatment (LDL <70 mg/dL for high-risk), antithrombotics (atrial fibrillation), smoking cessation, weight control, exercise (150 minutes of aerobic exercise per week). ECG screening for early detection of atrial fibrillation contributes to prevention of stroke and vascular dementia. Education on recognizing stroke warning symptoms (TIA, transient neurological symptoms) and going to the emergency room immediately is important.